Voya Global Advantage & Premium Opportunity Fund IGA 深滬

等待開盤 11-06 09:30:00 美东时间

9.5901

+0.000

+0.00%

華盛通

立即下載

最高9.639
今開9.615
成交量 5.24万股
最低 9.54
昨收 9.59
總市值 1.47亿
52周最高 9.935
市盈率 ^靜 6.39
換手率 0.34%
52周最低 7.835
委比 60.00%
總股本 1534.14万
歷史最高 9.639
量比 2.59
振幅 1.03%
歷史最低 1.036
每手 1
風險率 0.49%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea

10-24 20:33
Voya Global Advantage and Premium Opportunity Fund declares $0.085 dividend

Voya Global Advantage and Premium Opportunity Fund (NYSE:IGA) declares $0.085/share monthly dividend. Forward yield 10.26% Payable Nov. 17; for shareholders of record Nov. 3; ex-div Nov. 3. See IGA Di...

10-16 04:25
华东医药战略合作伙伴Arcutis宣布ZORYVE乳膏（0.05%）sNDA获美国FDA批准

（来源：华东医药股份有限公司）转自：华东医药股份有限公司近日，华东医药股份有限公司全资子公司杭州中美华东制药有限公司美国合作方 Arcutis Bioth...

10-13 16:34
Escalade Announces Acquisition of Gold Tip, a Leading Archery Brand, from Revelyst

EVANSVILLE, Ind. and PROVIDENCE, R.I., Sept. 29, 2025 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA), a leader in archery, sporting goods and indoor/outdoor recreation equipment, today announ...

09-29 18:00
重磅！阿斯利康达格列净大幅降价70%

达格列净片，由百时美施贵宝开发，是全球首款获批上市的SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，后全球销售权被阿斯利康收购。达格列净片最早于2012年...

09-29 11:24
AstraZeneca Rolls Out AstraZeneca Direct Platform For Patients To Access Prescribed Medicines With Home Delivery

AstraZeneca Direct is designed to offer greater convenienceAstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access

09-26 21:13
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

09-19 02:31
Nektar Therapeutics Announces New Data From Ongoing REZOLVE-AD Phase 2b Study Of Rezpegaldesleukin At 2025 EADV Congress

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitisHigh dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments

09-18 20:47
国金医药甘坛焕丨特应性皮炎专题研究：掘金百亿AD蓝海，现有疗法仍可优化，双抗药物有望破局

（来源：国金证券研究所）　　作者：甘坛焕、唐玉青摘要　　特应性皮炎以瘙痒作为重要标志，患者人群众多，疾病负担较重。特应性皮炎（AD）是一种慢性、复发性...

09-17 07:33
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.

09-10 03:06

派息除權日	每股總股息	派息日期
2025-11-03	0.09	2025-11-17
2025-10-01	0.09	2025-10-15
2025-09-02	0.09	2025-09-15
2025-08-04	0.09	2025-08-15
2025-08-01	0.09	2025-08-15
2025-07-01	0.09	2025-07-15
2025-06-02	0.09	2025-06-16
2025-05-01	0.09	2025-05-15
2025-04-01	0.09	2025-04-15
2025-03-03	0.09	2025-03-17
2025-02-03	0.09	2025-02-18
2024-12-30	0.09	2025-01-15
2024-12-02	0.09	2024-12-16
2024-11-01	0.09	2024-11-15
2024-10-01	0.09	2024-10-15
2024-09-04	0.09	2024-09-16
2024-09-03	0.09	2024-09-16
2024-08-01	0.09	2024-08-15
2024-07-01	0.09	2024-07-15
2024-06-03	0.09	2024-06-17
2024-05-01	0.09	2024-05-15
2024-04-01	0.20	2024-04-15
2023-12-28	0.20	2024-01-16
2023-10-02	0.20	2023-10-16
2023-07-03	0.20	2023-07-17
2023-04-03	0.20	2023-04-17
2022-12-29	0.20	2023-01-17
2022-10-03	0.20	2022-10-17
2022-07-01	0.20	2022-07-15
2022-04-01	0.20	2022-04-18
2021-12-30	0.20	2022-01-18
2021-10-01	0.20	2021-10-15
2021-07-01	0.20	2021-07-15
2021-04-01	0.20	2021-04-15
2020-12-30	0.20	2021-01-15
2020-10-01	0.20	2020-10-15
2020-07-01	0.20	2020-07-15
2020-04-01	0.20	2020-04-15
2019-12-30	0.20	2020-01-15
2019-10-01	0.20	2019-10-15
2019-07-01	0.22	2019-07-15
2019-04-01	0.22	2019-04-15
2018-12-28	0.22	2019-01-15
2018-10-01	0.22	2018-10-15
2018-07-02	0.22	2018-07-16
2018-04-02	0.22	2018-04-16
2017-12-28	0.22	2018-01-16
2017-10-03	0.22	2017-10-16
2017-07-03	0.22	2017-07-17
2017-04-03	0.22	2017-04-17
2016-12-28	0.22	2017-01-17
2016-10-03	0.28	2016-10-17
2016-07-01	0.28	2016-07-15
2016-04-01	0.28	2016-04-15
2015-12-29	0.28	2016-01-15
2015-10-01	0.28	2015-10-15
2015-07-01	0.28	2015-07-15
2015-04-01	0.28	2015-04-15
2014-12-29	0.28	2015-01-15
2014-10-01	0.28	2014-10-15
2014-07-01	0.28	2014-07-15
2014-04-01	0.28	2014-04-15
2013-12-27	0.28	2014-01-15
2013-10-01	0.28	2013-10-15
2013-07-01	0.28	2013-07-15
2013-04-01	0.28	2013-04-15
2012-12-27	0.28	2013-01-15
2012-10-01	0.28	2012-10-15
2012-07-02	0.31	2012-07-16
2012-04-02	0.31	2012-04-16
2011-12-28	0.31	2012-01-16
2011-10-03	0.34	2011-10-17
2011-07-01	0.34	2011-07-15
2011-04-01	0.34	2011-04-15
2010-12-29	0.34	2011-01-17
2010-10-01	0.34	2010-10-15
2010-07-01	0.34	2010-07-15
2010-04-01	0.37	2010-04-15
2009-12-29	0.37	2010-01-15
2009-10-01	0.47	2009-10-15
2009-06-30	0.47	2009-07-15
2009-04-01	0.47	2009-04-15
2008-12-29	0.47	2009-01-15
2008-10-01	0.47	2008-10-15
2008-07-01	0.47	2008-07-15
2008-04-01	0.47	2008-04-15
2007-12-27	1.58	2008-01-15
2007-10-01	0.47	2007-10-15
2007-07-02	0.47	2007-07-16
2007-04-02	0.47	2007-04-16
2006-12-27	0.47	2007-01-16
2006-10-02	0.47	2006-10-16
2006-07-03	0.47	2006-07-17
2006-03-29	0.47	2006-04-17
2005-12-28	0.16	2006-01-15

公司名稱	Voya Global Advantage & Premium Opportunity Fund
行業分類	--
業務描述	Voya Global Advantage & Premium Opportunity Fund operates as closed-end investment fund. Its portfolio includes current income, capital gains, and appreciation through equity security investment in Asia Pacific companies. The company was founded on October 26, 2005 and is headquartered in Scottsdale, AZ.

Voya Global Advantage & Premium Opportunity Fund IGA 深 滬

9.5901

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Voya Global Advantage & Premium Opportunity Fund IGA 深滬